Evoke Pharma Inc. (NASDAQ:EVOK) saw unusually-strong trading volume on Thursday . Approximately 23,999,608 shares were traded during mid-day trading, an increase of 881% from the previous session’s volume of 2,446,293 shares.The stock last traded at $3.15 and had previously closed at $2.05.

Several analysts have recently commented on EVOK shares. Brean Capital reiterated a “buy” rating on shares of Evoke Pharma in a report on Wednesday, April 6th. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a report on Tuesday, May 3rd. Rodman & Renshaw reiterated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Finally, FBR & Co reiterated a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Evoke Pharma presently has a consensus rating of “Hold” and an average price target of $13.34.

The company’s market capitalization is $18.97 million. The stock has a 50 day moving average price of $5.82 and a 200-day moving average price of $4.73.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. Analysts forecast that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.